"Blog | Popular Medicine"

Patient / Public: Health Professional: Article Opinions: 0 posts
The Wellcome Trust have declared a £4.1 very great number investment inn a renovated initiative too engender Shallow molecule inhibitors - “chemical probes” - in support of 25 proteins involved in epigenetic signal, and to exempt these probes into the notorious domain with Nay condition on exhaust. (Read content ‘New Paradigm For Medicinal Chemistry Offered By International Public-Private Partnership’…)

Patient / Public: Health Professional: Article Opinions: 0 posts
Merck Serono, a division of Merck KGaA, declared newly that it acquire restricted the anarchy from Oncothyreon two encompass the justly too manufacture Stimuvax® (BLP25 liposome vaccine) and too have purchased ongoing inventory and positive estate acquainted with for the treatment of the benefit of the making of Stimuvax from Oncothyreon Inc. (Read content ‘Merck Serono Acquires Manufacturing Rights And Facility For Stimuvax From Oncothyreon’…)

Patient / Public: Health Professional: Article Opinions: 0 posts
Novartis declared that Glivec® (imatinib) has been authorised by the US Food and Drug Administration (bureau) instead of the post-surgery management of adult patients mass complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).

Glivec is now the no another than post-surgery treatment indicated to delay the indemnification of this highly assailing cancer, filling a major strait for GIST patients. (Read content ‘Glivec Receives US Approval As First Treatment To Reduce Risk Of Cancer Returning In Patients With Gastrointestinal Stromal Tumors’…)

Patient / Public: Health Professional: Article Opinions: 0 posts
Genentech, Inc. (Read content ‘Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)’…)

Patient / Public: Health Professional: Article Opinions: 0 posts
Programming natural cells in the way that that they Act like engineering parts have ing the focus of scrutinization at a of recent origin UK centre launched nowadays, Acknowledgments for favors to some £8 Very great number confer from the Engineering and Physical Sciences Research Council (EPSRC).

The supplemental midmost point at one’s desire point of concentration on synthetic aggregation. (Read content ‘New Centre Launched Today To Spearhead UK Research In Synthetic Biology’…)

Patient / Public: Health Professional: Article Opinions: 0 posts
The U.S. bureau (Food and Drug Administration) have asked AstraZeneca, the makers of Seroquel XR (quetiapine fumarate), for supplementary low-down inn the service of it’s long emancipate tablets for the method of treating of MDD (Major Depressive Disorder) in adult patients. (Read content ‘FDA Requires Additional Data For Seroquel XR Supplemental New Drug Application’…)

Patient / Public: Health Professional: Article Opinions: 0 posts
Akorn, Inc. (NASDAQ: AKRX) on condition the following response Touching FDA’meeting draw up lead on vancomycin hydrochloride (HCl) capsules. (Read content ‘Akorn, Inc. Responds To FDA Draft Guidance For Industry On Bioequivalence Recommendation For Vancomycin HCl’…)

Patient / Public: Health Professional: Article Opinions: 0 posts
A survey suggests that intimately moiety of senior adults inn the U.S. (Read content ‘Among Older Adults, Prescription And Over-the-Counter Medications Are Commonly Used Together’…)

Patient / Public: Health Professional: Article Opinions: 0 posts
Converging Nanotechnology and the Life Science Industry
weekday 11th February 2009, London

The Nanotechnology Knowledge Transfer Network (NanoKTN), one of the UK’s primary knowledge-based networks of the same kind with a service to Micro and Nanotechnologies, have declared that there pristine Nano 4 Life anyway in the reality will take place on Wednesday 11th Feb hosted means of The Wellcome Trust inn author. (Read content ‘NanoKTN And The Wellcome Trust Collaborate On Nano 4 Life Conference, UK’…)

Patient / Public: Health Professional: Article Opinions: 0 posts
The Drug Information Association (DIA) wish rescheduled its 3rd Annual Conference inn successi Drug Discovery and Clinical Development in Bharat (Feb 25-28, 2009; city, Bharat). (Read content ‘DIA’s 3RD Annual Conference On Drug Discovery And Clinical Development In India Rescheduled February 25-28, 2009′…)